For decades, cancer drug developers have focused on inhibition. Now, a GV-backed startup is eyeing activation

Lei Lei Wu

News Reporter

One of the backbones of cancer medicine is shutting down key cancer-driving pathways to kill tumor cells. But for years, researchers have noticed hyperactivation of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

For decades, cancer drug developers have focused on inhibition. Now, a GV-backed startup is eyeing activation

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

For decades, can­cer drug de­vel­op­ers have fo­cused on in­hi­bi­tion. Now, a GV-backed start­up is eye­ing ac­ti­va­tion

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

For decades, cancer drug developers have focused on inhibition. Now, a GV-backed startup is eyeing activation